AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced milestones in the expected timeline for the ongoing Phase 2 clinical study ...

Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc. ("Astellas"), AstraZeneca and Bristol Myers Squibb to accelerate their global clinical develop ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

XLV gains, top S&P 500 winners/losers, and key earnings & deal news on AstraZeneca, CVS, Moderna & Lilly—read now.

WILMINGTON, DE — AstraZeneca began trading its ordinary shares on the New York Stock Exchange on Monday, February 2, 2026, marking a significant milestone as the global biopharmaceutical giant expands ...

The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 ...

SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca (AZN.L), opens new tab has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial ...

Add Yahoo as a preferred source to see more of our stories on Google. Syringes with needles are seen in front of a displayed AstraZeneca logo in this illustration taken, November 27, 2021.

On Tuesday, AstraZeneca Plc (NASDAQ: AZN) released complete results from the Phase 3 TULIP-SC trial of a subcutaneous (SC) administration of anifrolumab versus placebo in participants aged 18 to 70 ...

On Monday, AstraZeneca Plc (NASDAQ: AZN) released topline data from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi (durvalumab). The trial did not meet the primary endpoint of ...

AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...